Bio Elpida, facilities dedicated to the development of bio-pharmaceuticals
120 m² of Feasibility Laboratories
Bio Elpida provides two types of feasibility laboratories:
- 60 m² dedicated to the research and development for prokaryote cell programmes
- 60 m² dedicated to the research and development for eukaryotic cell programmes
Quality insurance and cGMP rules are applied as early as feasibility phases
A distinctive feature of Bio Elpida is to apply quality insurance and cGMP as early as feasibility phases. This approach ensures optimal transfer of processes to cGMP manufacturing and pharmaceutical zones as well as scale-up.